BR112019002387A2 - oligonucleotídeos antissenso de receptor de andrógeno - Google Patents
oligonucleotídeos antissenso de receptor de andrógenoInfo
- Publication number
- BR112019002387A2 BR112019002387A2 BR112019002387A BR112019002387A BR112019002387A2 BR 112019002387 A2 BR112019002387 A2 BR 112019002387A2 BR 112019002387 A BR112019002387 A BR 112019002387A BR 112019002387 A BR112019002387 A BR 112019002387A BR 112019002387 A2 BR112019002387 A2 BR 112019002387A2
- Authority
- BR
- Brazil
- Prior art keywords
- androgen receptor
- antisense oligonucleotides
- nucleic acid
- acid derivatives
- receptor antisense
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
são providos derivados de ácido nucleico de peptídeo que direcionam o sítio de emenda 5' do "éxon 5" dentro do pré-mrna humano de receptor de andrógeno. os derivados de ácido nucleico de peptídeo potencialmente induzem variantes de emenda de mrna de receptor de andrógeno nas células, e são úteis para tratar com segurança indicações ou condições dermatológicas que envolvem atividade androgênica, por administração tópica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662372035P | 2016-08-08 | 2016-08-08 | |
PCT/IB2017/000697 WO2018029517A1 (en) | 2016-08-08 | 2017-05-24 | Androgen receptor antisense oligonucleotides |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019002387A2 true BR112019002387A2 (pt) | 2019-06-04 |
Family
ID=61161927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019002387A BR112019002387A2 (pt) | 2016-08-08 | 2017-05-24 | oligonucleotídeos antissenso de receptor de andrógeno |
Country Status (13)
Country | Link |
---|---|
US (1) | US20190345202A1 (pt) |
EP (1) | EP3497114A4 (pt) |
JP (1) | JP7407592B2 (pt) |
KR (1) | KR102427575B1 (pt) |
CN (1) | CN110072879B (pt) |
AR (1) | AR109303A1 (pt) |
AU (1) | AU2017309347B2 (pt) |
BR (1) | BR112019002387A2 (pt) |
CA (1) | CA3032549A1 (pt) |
RU (1) | RU2753966C2 (pt) |
SG (1) | SG11201900153XA (pt) |
TW (1) | TWI775764B (pt) |
WO (1) | WO2018029517A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3046904A1 (en) * | 2016-12-30 | 2018-07-05 | Olipass Corporation | Exon skipping by peptide nucleic acid derivatives |
KR102483119B1 (ko) * | 2017-01-06 | 2023-01-02 | 올리패스 주식회사 | Snap25 안티센스 올리고뉴클레오타이드 |
WO2018138585A1 (en) * | 2017-01-24 | 2018-08-02 | Olipass Corporation | Scn9a antisense pain killer |
TWI832851B (zh) * | 2018-05-18 | 2024-02-21 | 韓商奧利通公司 | 基質金屬蛋白酶-1之反義寡核苷酸 |
KR102304280B1 (ko) * | 2018-08-14 | 2021-09-23 | 올리패스 주식회사 | 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3239393A (en) * | 1991-12-12 | 1993-07-19 | Scios Nova Inc. | Fluorenyl derivatives and their use as anti-inflammatory agents |
AU692148B2 (en) * | 1993-02-19 | 1998-06-04 | Genta Incorporated | Treatment of androgen-associated baldness using antisense oligomers |
US6133444A (en) | 1993-12-22 | 2000-10-17 | Perseptive Biosystems, Inc. | Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions |
US6617422B1 (en) * | 1997-05-23 | 2003-09-09 | Peter Nielsen | Peptide nucleic acid monomers and oligomers |
AU4494399A (en) * | 1998-06-30 | 2000-01-24 | University Of British Columbia, The | Inhibitors of androgen-independent activation of androgen receptor |
US20030207804A1 (en) * | 2001-05-25 | 2003-11-06 | Muthiah Manoharan | Modified peptide nucleic acids |
WO2005027833A2 (en) * | 2003-09-12 | 2005-03-31 | Avi Biopharma, Inc. | Compound and method for treating androgen-independent prostate cancer |
US8450290B2 (en) * | 2007-11-26 | 2013-05-28 | Enzon Pharmaceuticals, Inc. | Methods for treating androgen receptor dependent disorders including cancers |
AU2008329327B2 (en) * | 2007-11-26 | 2015-07-16 | Roche Innovation Center Copenhagen A/S | LNA antagonists targeting the androgen receptor |
KR20090098710A (ko) | 2008-03-14 | 2009-09-17 | 주식회사 씨티아이바이오 | 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체 |
ES2907254T3 (es) * | 2012-10-11 | 2022-04-22 | Ionis Pharmaceuticals Inc | Un compuesto antisentido modificado para su uso en el tratamiento de la enfermedad de Kennedy |
WO2018012261A1 (ja) | 2016-07-14 | 2018-01-18 | 株式会社日立製作所 | 電気品収容用筐体及びその製作方法 |
CA3046904A1 (en) * | 2016-12-30 | 2018-07-05 | Olipass Corporation | Exon skipping by peptide nucleic acid derivatives |
-
2017
- 2017-05-24 EP EP17838864.1A patent/EP3497114A4/en active Pending
- 2017-05-24 RU RU2019105298A patent/RU2753966C2/ru active
- 2017-05-24 SG SG11201900153XA patent/SG11201900153XA/en unknown
- 2017-05-24 US US16/324,266 patent/US20190345202A1/en active Pending
- 2017-05-24 WO PCT/IB2017/000697 patent/WO2018029517A1/en unknown
- 2017-05-24 AU AU2017309347A patent/AU2017309347B2/en active Active
- 2017-05-24 CN CN201780061959.8A patent/CN110072879B/zh active Active
- 2017-05-24 BR BR112019002387A patent/BR112019002387A2/pt unknown
- 2017-05-24 KR KR1020197005192A patent/KR102427575B1/ko active IP Right Grant
- 2017-05-24 CA CA3032549A patent/CA3032549A1/en active Pending
- 2017-05-24 JP JP2019507826A patent/JP7407592B2/ja active Active
- 2017-08-07 AR ARP170102220A patent/AR109303A1/es unknown
- 2017-08-07 TW TW106126503A patent/TWI775764B/zh active
Also Published As
Publication number | Publication date |
---|---|
RU2019105298A (ru) | 2020-09-11 |
US20190345202A1 (en) | 2019-11-14 |
AU2017309347A1 (en) | 2019-02-07 |
JP2019527720A (ja) | 2019-10-03 |
RU2753966C2 (ru) | 2021-08-24 |
RU2019105298A3 (pt) | 2020-10-08 |
SG11201900153XA (en) | 2019-02-27 |
CN110072879B (zh) | 2023-03-10 |
AU2017309347B2 (en) | 2020-11-19 |
TWI775764B (zh) | 2022-09-01 |
KR102427575B1 (ko) | 2022-08-01 |
EP3497114A4 (en) | 2020-04-29 |
WO2018029517A1 (en) | 2018-02-15 |
AR109303A1 (es) | 2018-11-21 |
CA3032549A1 (en) | 2018-02-15 |
JP7407592B2 (ja) | 2024-01-04 |
CN110072879A (zh) | 2019-07-30 |
KR20190055066A (ko) | 2019-05-22 |
EP3497114A1 (en) | 2019-06-19 |
TW201812009A (zh) | 2018-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019002387A2 (pt) | oligonucleotídeos antissenso de receptor de andrógeno | |
BR112017013597A2 (pt) | molécula de ácido nucleico, composição farmacêutica, vetor ou célula, e, método para tratamento de uma doença. | |
BR112018072279A2 (pt) | análogos de oligonucleotídeo tendo como alvo lmna humana | |
BR112017023380A2 (pt) | sistema, composição cosmética, métodos para tratamento de substratos queratinosos e para proteção e/ou alisamento da fibra do cabelo, kit multicompartimento, e, processo para alisamento do cabelo. | |
BR112018003985A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
BR112013006395A2 (pt) | moduladores do receptor de estrogênio e seus usos. | |
BR112018003316A2 (pt) | compostos e métodos para entrega transmembrana de moléculas | |
CL2016002312A1 (es) | Modulador del receptor de andrógeno y usos de este. | |
BR112014031088A2 (pt) | métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal | |
BR112018073329A2 (pt) | combinação, composição farmacêutica, kit, método para tratar câncer, método para reduzir um nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade, método para reduzir metástase | |
BR112019004322A2 (pt) | moduladores de receptor glicocorticoide para tratar câncer pancreático | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
BR112015001801A2 (pt) | métodos e composições para determinar a resistência à terapia de receptor de androgênio | |
BR112015009948A8 (pt) | Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios | |
BR112016022553A2 (pt) | Compostos e métodos para entrega transmembrana de moléculas? | |
BR112014030678A2 (pt) | formas cristalinas de um modulador de receptor de androgênio | |
BR112015023203A2 (pt) | métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos | |
BR112018016968A2 (pt) | derivados de carboxamida úteis como inibidores de rsk | |
UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
BR112017015310A2 (pt) | uso de pgr4 como um agente anti-inflamatório | |
BR112015023439A2 (pt) | combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki | |
BR112017020864A2 (pt) | inibidores de calicreína plasmática e usos dos mesmos para a prevenção de ataque de angioedema hereditário | |
BR112014003963A2 (pt) | compostos e composições como inibidores de quinase c-kit | |
BR112018011838A2 (pt) | terapia gênica para distúrbios oculares | |
BR112017026535A2 (pt) | composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |